Investor Presentaiton

BIOND BIOLOGICS BND-35 Program Gannt 2021 2022 2023 2024 MOA studies (In Vivo, Ex Vivo) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Lead Humanization CMC + GMP production IND enabling studies (TOX, TCR, In vitro safety PK, ADA, etc...) 7 Regulatory filing (Pre-IND, IND) Phase 1 Pre IND IND Biond Biologics Corporate Presentation | May 2021 | Non-confidential 30

View entire presentation